|Dr. Randal D. Chase Ph.D.||Pres, CEO & Director||N/A||N/A||67|
|Dr. Alexander Krantz Ph.D.||Founder, COO, Chief Scientific Officer, VP of Research & Director||175k||N/A||76|
|Mr. Kenneth Clifford Philippe||Chief Financial Officer||14.36k||N/A||65|
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. The company develops and commercializes a platform that is intended to use protein modification technologies to create human protein pharmaceuticals with therapeutic properties. Its proprietary technology targets cancerous tumors and avoids destroying normal cells. The company has collaboration with Heidelberg Pharma AG; and a collaboration and option agreement with ImmunoBiochem Corporation to develop antibody-drug conjugates. Advanced Proteome Therapeutics Corporation is headquartered in Boston, Massachusetts.
Advanced Proteome Therapeutics Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.